Merck’s Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early
Dateline City:
KENILWORTH, N.J.
KEYTRUDA Demonstrated Superior Overall Survival and Progression-Free Survival Compared to Ipilimumab
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the randomized, pivotal Phase 3 study (KEYNOTE-006)
investigating KEYTRUDA® (pembrolizumab) compared to
ipilimumab in the first-line treatment of patients with advanced
melanoma has met its two primary endpoints of progression-free survival
and overall survival. The trial will be stopped early based on the
recommendation of the study’s independent Data Monitoring Committee.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news